Status: Recruiting

Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease

This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.

Participants needed: 36

Trial details

Phase: Phase 1Age: 40-75Biological sex: AllType: InterventionalSponsor: Tridem Bioscience FlexCoUpdated: Sep 24, 2026Locations: 1

Eligibility criteria

Female or male patients aged 40-75 years old. Refer to section 5.3 for reproduct... [+5]

Known or suspected allergy, or history of anaphylaxis, to vaccines or their exci... [+14]

Status: Recruiting

An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.

An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy

Participants needed: 6

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tridem Bioscience FlexCoUpdated: Sep 10, 2026Locations: 1

Eligibility criteria

At least 18-years of age [+3]

Women of childbearing potential without use of contraception [+16]

Clinical trials

Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease

An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.